tnp-351 and Carcinoma--Small-Cell

tnp-351 has been researched along with Carcinoma--Small-Cell* in 1 studies

Other Studies

1 other study(ies) available for tnp-351 and Carcinoma--Small-Cell

ArticleYear
Growth inhibitory effects of antifolates against an adriamycin-resistant human small cell lung cancer cell line.
    Acta medica Okayama, 1997, Volume: 51, Issue:3

    We have established an Adriamycin (ADM)-resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM 100, which shows multifactorial mechanisms of resistance to ADM, such as over-expression of P-glycoprotein, an enhanced detoxifying system and a decrease in topoisomerase II activity. In the present study, we confirmed that SBC-3/ADM 100 showed collateral sensitivity to methotrexate and TNP-351, a new antifolate, though this cell line showed a typical multidrug resistance (MDR) pattern. We also demonstrated a faster uptake and higher accumulation (1.3-fold) of TNP-351 in the SBC-3/ADM 100 cells than those in the parent SBC-3 cells. These results explain one of the mechanisms for collateral sensitivity in the resistant cells. Furthermore, this cell line was found to have no cross-resistance to edatrexate and minimal cross-resistance to trimetrexate, 254-S (cisplatin analog), 5-fluorouacil and 4-hydroperoxyifosfamide. These drugs will have clinical importance in patients with SCLC who were previously treated with an ADM-containing regimen. Thus, antifolates, especially TNP-351 and edatrexate, can be expected to eradicate residual multidrug resistant SCLC cells selected by ADM.

    Topics: Animals; Carcinoma, Small Cell; Cell Cycle; Doxorubicin; Drug Resistance, Neoplasm; Folic Acid Antagonists; Growth Inhibitors; Humans; Intracellular Fluid; Lung Neoplasms; Methotrexate; Rabbits; Tumor Cells, Cultured

1997